Decoy Therapeutics Inc. (DCOY )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol DCOY
- Company Decoy Therapeutics Inc.
- Price $7.58
- Changes Percentage 1201.56
- Change 7.00
- Day Low $0.53
- Day High $7.58
- Year High $415.8
- Year Low $0.53
- Market Cap $48,402,299
- Price Avg 50 EMA (D) $8.96
- Price Avg 200 EMA (D) $57.87
- Exchange NASDAQ
- Volume 166,633
- Average Volume 191,753
- Open $0.54
- Previous Close $0.58
- EPS -290.88
- PE -0.03
- Earnings Announcement 2026-03-30 12:00:00
- Shares Outstanding $6,384,180
Company brief: DECOY THERAPEUTICS INC. (DCOY )
- Healthcare
- Biotechnology
- Frederick E. Pierce
- https://www.salariuspharma.com
- US
- N/A
- 01-29-2015
- US79400X5032
Salarius Pharmaceuticals, Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing. Its IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, optimize, and manufacture peptide conjugates targeting various unmet medical needs. The company focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology. Salarius Pharmaceuticals, Inc. is based in Houston, Texas.
DCOY Corporation News
Decoy Therapeutics Announces 1-for-12 Reverse Stock Split
prnewswire.com -- CAMBRIDGE, Mass., March 5, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (NASDAQ: DCOY), a preclinical-stage biopharmaceutical company that is engineering the next generation of peptide conjugate thera...